MKI67 and neoplasm: The end goal of this trial is analysing changes in gene proliferation measured by tumour cell Ki67 immunohistochemistry to generate insights into the tumor microenvironment and identify biomarkers that may guide future therapeutic strategies for chemotherapy-resistant disease [68].